SOPHiA GENETICS And AstraZeneca Collaborate To Further Expand Global Access To Liquid Biopsy Testing; SOPHiA GENETICS Will Accelerate The Deployment Of MSK-ACCESS Powered With SOPHiA DDM To 20 Locations Worldwide Over The Next 12 Months
SOPHiA GENETICS And AstraZeneca Collaborate To Further Expand Global Access To Liquid Biopsy Testing; SOPHiA GENETICS Will Accelerate The Deployment Of MSK-ACCESS Powered With SOPHiA DDM To 20 Locations Worldwide Over The Next 12 Months
The companies commit to bring cutting-edge liquid biopsy testing to 20 institutions globally over the next 12 months
两家公司承诺在未来12个月内为全球20个机构提供尖端的液体活检测试
BOSTON and ROLLE, Switzerland, Sept. 10, 2024 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ:SOPH), a cloud-native healthcare technology company and a global leader in data-driven medicine, today announced a new milestone in the global introduction of the liquid biopsy test MSK-ACCESS powered with SOPHiA DDM, first announced in October 2023. Under a definitive partnership agreement with AstraZeneca (NASDAQ:AZN), SOPHiA GENETICS will accelerate the deployment of MSK-ACCESS powered with SOPHiA DDM to 20 locations worldwide over the next 12 months.
波士顿和瑞士罗尔，2024年9月10日 /PRNewswire/ — 云原生医疗保健技术公司、数据驱动医学领域的全球领导者SopHia Genetics（纳斯达克股票代码：SOPH）今天宣布了全球推出基于SopHia dDM的液体活检测试msK-Access的新里程碑，该测试于2023年10月首次发布。根据与阿斯利康（纳斯达克股票代码：AZN）签订的最终合作协议，SopHia GENETICS将在未来12个月内加快在全球20个地点部署由SopHia dDM提供支持的MSK-Access。
